论文部分内容阅读
选取T2DM患者89例,分为尿NA组、MA尿组和DN组。结果DN组PAI-1水平明显高于尿NA组(P<0·01)和MA组(P<0.05),t-PA/PAI-1比值显著低于尿NA组(P<0.01)和MA尿组(P<0.05),MA组t-PA及t-PA/PAI-1水平显著低于尿NA的患者(P<0.05,P<0.01)。DN组t-PA明显低于MA组(P<0.01)。予罗格列酮治疗后,PPG、HbA1C、尿MA、PAI-1水平明显下降(P<0.05,P<0.01),t-PA、t-PA/PAI-1水平明显增加(P<0·05,P<0·01)。结论盐酸罗格列酮可提高t-PA水平、降低PAI-1水平,改善纤溶活性,延缓肾功能损害。
Eighty-two patients with T2DM were selected and divided into urinary NA group, MA urinary group and DN group. Results The PAI-1 level in DN group was significantly higher than that in NA group (P <0.01) and MA group (P <0.05), and the ratio of t-PA / PAI- (P <0.05). The levels of t-PA and t-PA / PAI-1 in MA group were significantly lower than those in urine NA group (P <0.05, P <0.01). The t-PA in DN group was significantly lower than that in MA group (P <0.01). After rosiglitazone treatment, the levels of PPG, HbA1C, urine MA and PAI-1 were significantly decreased (P <0.05, P <0.01) and the levels of t-PA and PAI-PA were significantly increased 05, P <0.01). Conclusion Rosiglitazone hydrochloride can increase the level of t-PA, decrease the level of PAI-1, improve the fibrinolytic activity and delay the renal damage.